Com, thanks, Theo, Hey everyone. We're so excited to be with you today to talk about this deal with not an artist and Eli Lilly, as you know, from the very beginning when the President announced this executive order, GLP, ones have been top of mind, and not because of their just because of the cardio metabolic benefits that they provide, but also because this is again, an issue of fairness and in equalization and pricing and access and affordability for the American people. So I'm going to jump in and talk to you about the contours of the deal, and then, of course, we'll be glad to do some questions on the back end if there are things you'd like to clarify with the team. So first, as Theo mentioned, this is the belt suspenders deal. We are starting first with all the customary, most favored nation terms that you've heard about in the prior announcements and that we're securing with every pharmaceutical company pursuing the executive order and the President's letter to the pharmaceutical CEOs over the summer, that means full Medicaid portfolios at most favored nation prices immediately shared savings from existing foreign drug foreign price increases as efforts by us, Trade Representative and the Department of Commerce proves successful, all primary care drugs are nearly all primary care drugs across the manufacturers portfolios, available, at least at us, net prices, and in many instances, MSN prices, most favored nation prices available on Trump RX, when it launches in early 2026 and then, of course, and perhaps Most importantly, all future drug launches across all of commercial, Medicare, Medicaid and cash markets at the most favored nation pricing. So we are already very pleased with it, with two major pharmaceutical manufacturers, Novo and Lily. But in this deal, as Theo mentioned, there's a special weight. There's more. So we're focused on GLP ones today. I won't go through the history of this. We'll jump straight to the good stuff, which is first and foremost, oral doses. Starting oral doses of GLP ones will cost just $149 for everyone on Medicare, Medicaid or Trump, RX. That's roughly 1/9 of today's list price for Medicare, the manufacturers have voluntarily agreed to reduce prices on GLP, ones currently used for diabetes and other covered indications, to $245 per month across all other doses. This is noticeable or notable. This is a reduction in prices on drugs that we are already paying for in Medicare. The savings generated by these price reductions will then be used to provide new coverage for GLP ones to patients with obesity at high metabolic or cardiovascular risk, again, all at the same $245 per month. Now, let me spend just a minute about what we mean by heart, metabolic or cardiovascular risk. Think about this as three tiers that we'll get into, and we're happy again to answer questions along the way, but first, patients who are overweight with pre diabetes or established cardiovascular disease, so think of this as BMI greater than 27 second is patients with obesity and uncontrolled hypertension, kidney disease, heart failure. This will be a class of BMI greater than 30 and then patients with severe obesity. So anyone with BMI greater than 35 those are the three cohorts of patients and Medicare who will have access to these drugs for purposes of obesity and for driving benefit across cardio metabolic improvement. So what this means is that patients struggling with these can now access these life changing treatments affordably, and by that we specifically mean Medicare patients will only pay a copay of $50 for any approved indication for Medicaid, Nova and Lily have also agreed to extend their new low government pricing to all 50 state Medicaid programs for all covered indications. Again, this includes diabetes and current covered indications, as well as new indications as just described for obesity, that's the same $245 per month across all other non starting doses. States will have the opportunity to opt into these prices, and we of course, encourage them to doing so as soon as practical on Trump RX, the average price of injectables and borrows will be at or below $350 to start. This compares to $500 roughly today. That will trend down to the same $245 over 24 months. So again, that's $149 to start, and then $245 or less on average for every American at steady state, that's 1/5 to list price. It's nearly half off the best price anywhere in the United States today. So I want to highlight two other quick points. First, this really isn't about just spending more in Medicare. We're highlighting the idea that we are reducing prices for Medicare beneficiaries right now who are taking GLP ones for diabetes by nearly half, and we're using those savings to pay for additional indications. This isn't just about losing weight. This is about getting fitter. It's about getting healthier. And we believe there are 10s of billions of dollars of additional savings beyond the fact that this is already a nearly cost neutral deal to improve health information. So with that, I'll pause jump to questions. Do you want to have any okay?